Thomas Tousseyn
Universitaire Ziekenhuizen Leuven
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Thomas Tousseyn.
Blood | 2014
Sandrine Degryse; Charles E. de Bock; Luk Cox; Sofie Demeyer; Olga Gielen; Nicole Mentens; Kris Jacobs; Ellen Geerdens; Valentina Gianfelici; Gert Hulselmans; Mark Fiers; Stein Aerts; J Meijerink; Thomas Tousseyn; Jan Cools
JAK3 is a tyrosine kinase that associates with the common γ chain of cytokine receptors and is recurrently mutated in T-cell acute lymphoblastic leukemia (T-ALL). We tested the transforming properties of JAK3 pseudokinase and kinase domain mutants using in vitro and in vivo assays. Most, but not all, JAK3 mutants transformed cytokine-dependent Ba/F3 or MOHITO cell lines to cytokine-independent proliferation. JAK3 pseudokinase mutants were dependent on Jak1 kinase activity for cellular transformation, whereas the JAK3 kinase domain mutant could transform cells in a Jak1 kinase-independent manner. Reconstitution of the IL7 receptor signaling complex in 293T cells showed that JAK3 mutants required receptor binding to mediate downstream STAT5 phosphorylation. Mice transplanted with bone marrow progenitor cells expressing JAK3 mutants developed a long-latency transplantable T-ALL-like disease, characterized by an accumulation of immature CD8(+) T cells. In vivo treatment of leukemic mice with the JAK3 selective inhibitor tofacitinib reduced the white blood cell count and caused leukemic cell apoptosis. Our data show that JAK3 mutations are drivers of T-ALL and require the cytokine receptor complex for transformation. These results warrant further investigation of JAK1/JAK3 inhibitors for the treatment of T-ALL.
Case Reports | 2016
Eva ter Haar; Veerle Labarque; Thomas Tousseyn; Djalila Mekahli
We discuss a case of acute kidney injury (AKI) at a very young age caused by primary lymphomatous renal infiltration due to Burkitts lymphoma and analyse the literature on this rare condition. At presentation, clinical examination showed impressive bilateral nephromegaly and hypertension. Blood analysis indicated severe AKI, mild anaemia and normal serum electrolytes. There were no signs of tumour lysis syndrome. Urine sediment was normal, with neither haematuria nor proteinuria. Abdominal ultrasound demonstrated bilateral renal enlargement (+12 SD), with increased corticomedullar differentiation. MRI demonstrated the presence of a homogenous renal enlargement with features of an infiltrative lesion. Ultimately, microscopic and immunohistochemical analysis of the renal biopsy confirmed the diagnosis of Burkitts lymphoma. Early and aggressive therapy is the key to ensure a good outcome.
Archive | 2017
Sophie Van Aelst; Helena Claerhout; C Melis; Thomas Tousseyn; Peter Vandenberghe; Daan Dierickx; Nancy Boeckx
Archive | 2017
Lukas Marcelis; Julie Morscio; Julio Finalet Ferreiro; Sara Vander Borght; Emilie Bittoun; Olivier Gheysens; Daan Dierickx; Gregor Verhoef; Iwona Wlodarska; Thomas Tousseyn
Archive | 2016
Helena Maes; J Maertens; Sanne Smits; Els Lierman; Nancy Boeckx; Thomas Tousseyn; Gregor Verhoef; Peter Vandenberghe
Abstract book | 2016
Jo-Anne van der Krogt; Julio Finalet Ferreiro; Kris Jacobs; Ellen Geerdens; Anne Uyttebroeck; Peter Vandenberghe; Thomas Tousseyn; Jan Cools; Iwona Wlodarska
Archive | 2015
Julie Morscio; Julio Finalet Ferreiro; Daan Dierickx; Gregor Verhoef; Iwona Wlodarska; Thomas Tousseyn
Archive | 2014
Julie Morscio; Thomas Tousseyn
Archive | 2013
Helena Maes; Gregor Verhoef; Dirk Kuypers; Patrick Schöffski; Thomas Tousseyn; Michel Delforge; Timothy Devos; Ann Janssens; Johan Maertens; Hélène Schoemans; Daan Dierickx
Archive | 2013
Daan Dierickx; Thomas Tousseyn; Julie Morscio; Steffen Fieuws; Gregor Verhoef